THX PHARMA SACA (ALTHX.PA) Fundamental Analysis & Valuation

EPA:ALTHX • FR0013286259

3.25 EUR
+0.05 (+1.56%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This ALTHX.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

Overall ALTHX gets a fundamental rating of 0 out of 10. We evaluated ALTHX against 50 industry peers in the Pharmaceuticals industry. ALTHX has a bad profitability rating. Also its financial health evaluation is rather negative. ALTHX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. ALTHX.PA Profitability Analysis

1.1 Basic Checks

  • ALTHX had negative earnings in the past year.
  • In the past year ALTHX has reported a negative cash flow from operations.
  • In the past 5 years ALTHX always reported negative net income.
  • ALTHX had a negative operating cash flow in each of the past 5 years.
ALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • With a Return On Assets value of -64.91%, ALTHX is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -64.91%
ROE N/A
ROIC N/A
ROA(3y)-65.38%
ROA(5y)-54.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTHX.PA Yearly ROA, ROE, ROICALTHX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALTHX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTHX.PA Yearly Profit, Operating, Gross MarginsALTHX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ALTHX.PA Health Analysis

2.1 Basic Checks

  • ALTHX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALTHX has been increased compared to 5 years ago.
  • The debt/assets ratio for ALTHX is higher compared to a year ago.
ALTHX.PA Yearly Shares OutstandingALTHX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALTHX.PA Yearly Total Debt VS Total AssetsALTHX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • ALTHX has an Altman-Z score of 0.76. This is a bad value and indicates that ALTHX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.76, ALTHX is doing worse than 75.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.76
ROIC/WACCN/A
WACCN/A
ALTHX.PA Yearly LT Debt VS Equity VS FCFALTHX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 0.93 indicates that ALTHX may have some problems paying its short term obligations.
  • The Current ratio of ALTHX (0.93) is worse than 81.63% of its industry peers.
  • ALTHX has a Quick Ratio of 0.93. This is a bad value and indicates that ALTHX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALTHX has a Quick ratio (0.93) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
ALTHX.PA Yearly Current Assets VS Current LiabilitesALTHX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALTHX.PA Growth Analysis

3.1 Past

  • ALTHX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.71%.
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1140%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 69.31% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y69.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTHX.PA Yearly Revenue VS EstimatesALTHX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2021 5M 10M 15M
ALTHX.PA Yearly EPS VS EstimatesALTHX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALTHX.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALTHX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALTHX is valuated quite expensively with a Price/Forward Earnings ratio of 31.55.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ALTHX indicates a slightly more expensive valuation: ALTHX is more expensive than 67.35% of the companies listed in the same industry.
  • ALTHX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 24.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 31.55
ALTHX.PA Price Earnings VS Forward Price EarningsALTHX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTHX.PA Per share dataALTHX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • ALTHX's earnings are expected to grow with 69.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.31%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALTHX.PA Dividend Analysis

5.1 Amount

  • ALTHX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALTHX.PA Fundamentals: All Metrics, Ratios and Statistics

THX PHARMA SACA

EPA:ALTHX (3/6/2026, 7:00:00 PM)

3.25

+0.05 (+1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-20
Earnings (Next)N/A
Inst Owners5.54%
Inst Owner ChangeN/A
Ins Owners4.81%
Ins Owner ChangeN/A
Market Cap44.85M
Revenue(TTM)N/A
Net Income(TTM)-2.94M
Analysts86.67
Price Target4.49 (38.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 31.55
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.1
Fwd EY3.17%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS-0.14
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.91%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.38%
ROA(5y)-54.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 172.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z 0.76
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.38%
Cap/Depr(5y)30.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1140%
EPS Next Y13.33%
EPS Next 2Y69.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.22%
OCF growth 3YN/A
OCF growth 5YN/A

THX PHARMA SACA / ALTHX.PA FAQ

What is the ChartMill fundamental rating of THX PHARMA SACA (ALTHX.PA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ALTHX.PA.


Can you provide the valuation status for THX PHARMA SACA?

ChartMill assigns a valuation rating of 1 / 10 to THX PHARMA SACA (ALTHX.PA). This can be considered as Overvalued.


How profitable is THX PHARMA SACA (ALTHX.PA) stock?

THX PHARMA SACA (ALTHX.PA) has a profitability rating of 0 / 10.